Pasithea Therapeutics Secures $60M Funding to Advance Pipeline and Extend Cash Runway

Pasithea Therapeutics Corp. priced a $60 million public offering at $0.75 per share, led by healthcare-focused investors. The financing is expected to close on Dec. 1, 2025, and the net proceeds will extend the company's cash runway through at least the first half of 2028. The company's lead candidate, PAS-004, is a next-generation oral MEK inhibitor for RASopathies and other diseases, currently in Phase 1 trials.